Nuvation Bio Q2 Revenue Beats Consensus, CEO Adopts 10b5-1 Plan, Pipeline Advances

summarizeSummary

Nuvation Bio's Q2 revenue beat estimates, CEO David Hung adopted a 10b5-1 plan to sell up to 2 million shares, and the company advanced its pipeline with an FDA acceptance and new safusidenib studies.

check_boxKey Events · Earnings and Guidance · NUVB

• Q2 Revenue Beat

  Revenue of $31.69 million exceeded the $27.51 million consensus, driven by a 25% sequential increase in IBTROZI sales.

• CEO 10b5-1 Plan

  CEO David Hung adopted a Rule 10b5-1 trading plan on May 27, 2026, to sell up to 2,000,000 shares beginning September 25, 2026.

• Pipeline Advances

  FDA accepted a supplemental NDA for IBTROZI with a target action date of January 4, 2027; two new safusidenib studies announced — a pivotal Phase 3 in grade 2 IDH1-mutant glioma and a Phase 2 in post-vorasidenib patients.

• Strong Cash Position

  Cash, equivalents, and marketable securities totaled $661.0 million as of June 30, 2026, following the completion of a $287.5 million convertible notes offering in July 2026.

auto_awesomeAnalysis · NUVB · Life Sciences

Nuvation Bio reported Q2 revenue of $31.69 million, beating the $27.51 million consensus, driven by a 25% sequential increase in IBTROZI sales. The company also disclosed that CEO David Hung adopted a 10b5-1 trading plan to sell up to 2 million shares starting in September 2026 — a notable insider sale signal. On the pipeline front, the FDA accepted a supplemental NDA for IBTROZI with a January 2027 decision date, and the company announced two new safusidenib studies. The balance sheet remains strong with $661 million in cash and equivalents, bolstered by the completion of a $287.5 million convertible notes offering in July 2026. The combination of a revenue beat, insider selling, and multiple pipeline catalysts makes this a significant update for investors.